14,672 Shares in Insulet Corporation $PODD Purchased by Aurora Investment Counsel

Aurora Investment Counsel purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,672 shares of the medical instruments supplier's stock, valued at approximately $2,234,000.

A number of other large investors have also added to or reduced their stakes in PODD. BlackRock Inc. bought a new stake in Insulet in the second quarter worth about $1,018,582,000. State Street Corp lifted its stake in Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier's stock valued at $896,916,000 after purchasing an additional 65,317 shares during the last quarter. Geode Capital Management LLC grew its holdings in Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier's stock valued at $568,274,000 after purchasing an additional 41,019 shares during the period. Invesco Ltd. grew its holdings in Insulet by 10.5% during the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier's stock valued at $420,835,000 after purchasing an additional 141,167 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its position in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after buying an additional 1,011,369 shares during the last quarter.

Insulet Stock Up 2.4%

PODD opened at $151.51 on Thursday. The firm has a market capitalization of $10.51 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 1.17 and a beta of 1.10. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a fifty day moving average price of $154.75 and a 200-day moving average price of $185.83. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83.

Insulet (NASDAQ:PODD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The company had revenue of $801.70 million for the quarter, compared to the consensus estimate of $787.39 million. During the same quarter last year, the business posted $1.17 earnings per share. The firm's revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Equities research analysts expect that Insulet Corporation will post 6.51 earnings per share for the current fiscal year.

Insider Activity at Insulet

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the transaction, the director owned 9,041 shares in the company, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.36% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Bank of America cut their price target on Insulet from $288.00 to $208.00 and set a "buy" rating for the company in a research note on Monday, May 18th. Wall Street Zen cut Insulet from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 9th. Barclays dropped their price objective on shares of Insulet from $286.00 to $198.00 and set an "underweight" rating on the stock in a report on Thursday, May 7th. BTIG Research lowered shares of Insulet from a "buy" rating to a "neutral" rating in a research report on Thursday, August 6th. Finally, Weiss Ratings downgraded shares of Insulet from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, June 24th. Fourteen analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $195.40.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s recent operating performance provides a counterpoint to the legal concerns: the company’s latest reported quarter exceeded analyst expectations for both earnings and revenue, with revenue up 23.5% year over year. This may be supporting investor confidence.
• Neutral Sentiment: Multiple firms, including Glancy Prongay Wolke & Rotter, Robbins LLP, Rosen Law Firm, Portnoy Law Firm, and others, are soliciting investors who purchased Insulet securities between February 21, 2025, and May 26, 2026. The firms cite a federal securities class action and an August 31, 2026 deadline for investors to seek appointment as lead plaintiff. Deadline Alert: Insulet Corporation Shareholders
• Negative Sentiment: The complaints allege that Insulet made materially false or misleading statements about manufacturing controls and the safety and reliability of its Omnipod insulin-delivery products. The allegations reportedly center on two voluntary medical-device corrections and claims that broader manufacturing defects were not adequately disclosed. The allegations have not been proven in court. Insulet Corporation Stockholders Class Action
• Negative Sentiment: One law-firm notice says investor confidence deteriorated after the Omnipod corrections and attributes an approximately $90-per-share decline to the alleged disclosures. If the litigation produces further recalls, regulatory action, settlements, or evidence of persistent quality problems, Insulet could face higher costs and slower growth. PODD Deadline Alert from Levi & Korsinsky

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source